α4β2-Nicotine acetylcholine receptor: advances in relevant diseases and drugs
10.16438/j.0513-4870.2020-0677
- VernacularTitle:烟碱α4β2型受体与相关疾病及药物研究进展
- Author:
De-wen KONG
;
Zi-ru YU
;
Qi-meng ZHOU
;
Guan-hua DU
- Publication Type:Research Article
- Keywords:
nicotine acetylcholine receptor;
italic>α4β2;
nervous system disease;
rug
- From:
Acta Pharmaceutica Sinica
2021;56(1):1-8
- CountryChina
- Language:Chinese
-
Abstract:
The α4β2-nicotinic acetylcholine receptor (nAChR) is a ligand-gated ion channel that is distributed throughout the nervous system. It is involved in the regulation of various neurotransmitters including acetylcholine, dopamine, γ-aminobutyric acid, and norepinephrine. α4β2-nAChR plays an important role in learning, memory, cognition, attention, inflammation, and pain. A large number of studies have shown that α4β2-nAChR is an important therapeutic target for neurological diseases such as Alzheimer's disease, Parkinson's disease, epilepsy, depression, nicotine dependence, pain, etc. It is an important target in the early diagnosis and curative effect detection of neurodegenerative diseases including Alzheimer's disease. This review summarizes the role, mechanisms and related drug research advances on α4β2-nAChR ligand drugs in neurological diseases, as well as providing a theoretical basis for identifying and developing more suitable α4β2-nAChR-related compounds.
